ArticleImmunity, inflammation and disease2025
Aurantio-Obtusin Suppresses Airway Inflammation and Serum ICAM-1 Expression in Guinea Pig Allergic Asthma Model.
Article in Immunity, inflammation and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionAurantio-obtusin is a trihydroxyanthraquinone found in the seeds of Cassia tora and Cassia obtusifolia. Its neuroprotective, anti-inflammatory, anti-allergic, and antioxidant potential has been documented in multiple studies. While previous reports mention its potential as an antiasthma agent, its effects on allergen-induced airway inflammation have not been explored.
methodOur study reports on the mechanisms by which aurantio-obtusin exerts its effects on underlying inflammation in experimentally-induced allergic asthma. The effect of aurantio-obtusin pretreatment on molecular and histological changes in guinea pig lungs when challenged with aerosolized ovalbumin was assessed.
resultsOur results showed that aurantio-obtusin significantly reduced ovalbumin (OVA)-induced increase in serum OVA-specific immunoglobulin E (OVA-sIgE) and intercellular adhesion molecule (ICAM)-1. Aurantio-obtusin further suppressed inflammatory cytokine expression (IL-8, TNF-α, IL-6 and thymic stromal lymphopoietin) as well as malondialdehyde, a product of oxidative stress in bronchial lavage. The histopathological assessment showed a reduced transit of inflammatory cells and reduced deposition of collagen in the lungs of aurantio-obtusin-treated guinea pigs.
conclusionOverall, the data suggests that aurantio-obtusin mitigated ovalbumin-induced airway inflammation by impeding the production of OVAsIgE and suppressing levels of key pro-inflammatory cytokines. Our findings suggest that aurantio-obtusin has potential benefits in the management of allergic airway inflammation in type 2 asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.